Lupin and its US based subsidiary Lupin Pharmaceuticals, Inc., have settled all ongoing litigation over Lunesta (Eszopicolone) tablets, thereby dismissing a patent suit brought by Dainippon Sumitomo Pharma Co's subsidiary Sunovion Pharmaceuticals Inc.

The settlement entitles Lupin to sell its generic version of Lunesta under a license as soon as November 30, 2013. The date would be pushed back to May 31, 2014, if Sunovion obtains six months additional paediatric exclusivity for the product. Sales of Lunesta were $787 million in the 12 months ended September 2010.

Lupin Pharmaceuticals, Inc., headquartered in Baltimore, Maryland, is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies.